［1］KEIR ME,BUTTE MJ,FREEMAN GJ,et al.PD-1 and its ligands in tolerance and immunity［J］.Annu Rev Immunol,2008,26:677-704.
［2］SHITARA K,VAN CUTSEM E,BANG YJ,et al.Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line,advanced gastric cancer:the KEYNOTE-062 phase 3 randomized clinical trial［J］.JAMA Oncology,2020,6(10):1571-1580.
［3］MARABELLE A,LE DT,ASCIERTO PA,et al.Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer:Results from the phase Ⅱ KEYNOTE-158 study［J］.Journal of Clinical Oncology,2020,38(1):1.
［4］刘玄勇,郭智,谢晶,等.PD-1 抑制剂在弥漫大 B 细胞淋巴瘤维持治疗中的作用:单中心回顾性病例对照研究［J］.中国癌症防治杂志,2021,13(4):359-364.
LIU XY,GUO Z,XIE J,et al.Efficacy of PD-1 inhibitors in the maintenance treatment for diffuse large B-cell lymphoma:A single-center retrospective case-control study［J］.Chinese Journal of Oncology Prevention and Treatment,2021,13(4):359-364.
［5］艾超,冀召帅,唐蕾,等.PD-1/ PD-L1抑制剂抗肿瘤临床研究进展［J］.临床药物治疗杂志,2021,19(9):8-13.
AI C,JI ZS,TANG L,et al.Research progress on anticancer effects of PD-1/ PD-L1 inhibitors［J］.Clinical Medication Journal,2021,19(9):8-13.
［6］TANEGASHIMA T,TOGASHI Y,AZUMA K,et al.Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity［J］.Clinical Cancer Research,2019,25(15):4808-4819.
［7］袁风玲,贾淑慧,江源.卵巢癌组织中PD-L1及PD-L2的表达及其预后判断价值［J］.实用癌症杂志,2020,35(10):1622-1624,1638.
YUAN FL,JIA SH,JIANG Y.The expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer［J］.The Practical Journal of Cancer,2020,35(10):1622-1624,1638.
［8］隋启海,詹成,马可,等.食管鳞状细胞癌(ESCC)中PD-1/PD-L1/PD-L2的表达与临床因素及预后的相关性［J］.复旦学报(医学版),2020,47(1):76-82,100.
SUI QH,ZHAN C,MA K,et al.Connection of PD-1/PD-L1/PD-L2 expression with clinical factors and prognosis in esophageal squamous cell carcinoma(ESCC)［J］.Fudan University Journal of Medical Sciences,2020,47(1):76-82,100.
［9］TSENG SY,OTSUJI M,GORSKI K,et al.B7-DC,a new dendritic cell molecule with potent costimulatory properties for T cells［J］.J Exp Med,2001,193:839-846.
［10］张秀萍,李智勇,王志明.程序性死亡受体配体2在实体瘤免疫治疗中的研究进展［J］.肿瘤研究与临床,2021,33(9)：641-644.
ZHANG XP,LI ZY,WANG ZM.Progress of programmed death ligand 2 in immunotherapy of solid tumors［J］.Cancer Research and Clinic,2021,33(9):641-644.
［11］ZHENG B,REN T,HUANG Y,et al.PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse［J］.Journal of Hematology & Oncology,2018,11(1):1-13.
［12］SOLINAS C,AIELLO M,ROZALI E,et al.Programmed cell death-ligand 2:A neglected but important target in the immune response to cancer［J］.Translational Oncology,2020,13(10):100811.
［13］TANG S,KIM PS.A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery［J］.Proceedings of the National Academy of Sciences,2019,116(49):24500-24506.
［14］LATCHMAN Y,WOOD CR,CHERNOVA T,et al.PD-L2 is a second ligand for PD-1 and inhibits T cell activation［J］.Nature Immunology,2001,2(3):261-268.
［15］SHENG QJ,TIAN WY,DOU XG,et al.Programmed death 1,ligand 1 and 2 correlated genes and their association with mutation,immune infiltration and clinical outcomes of hepatocellular carcinoma［J］.World Journal of Gastrointestinal Oncology,2020,12(11):1255.
［16］SUDO S,KAJIYA H,OKANO S,et al.Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma［J］.Cancer Science,2020,111(4):1113-1123.
［17］YEARLEY JH,GIBSON C,YU NI,et al.PD-L2 expression in human tumors:relevance to anti-PD-1 therapy in cancer［J］.Clinical Cancer Research,2017,23(12):3158-3167.
［18］QIAO Y,LIU C,ZHANG X,et al.PD-L2 based immune signature confers poor prognosis in HNSCC［J］.Oncoimmunology,2021,10(1):1947569.
［19］OKADOME K,BABA Y,YASUDA-YOSHIHARA N,et al.PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma［J］.Cancer Science,2022,113(2):399.
［20］ROZALI EN,HATO SV,ROBINSON BW,et al.Programmed death ligand 2 in cancer-induced immune suppression［J］.Clinical and Developmental Immunology,2012,2012:656340.
［21］ALLISON JP.PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells［J］.Proceedings of the National Academy of Sciences,2003,100(9):5336-5341.
［22］DERKS S,NASON KS,LIAO X,et al.Epithelial PD-L2 expression marks Barrett's esophagus and esophageal adenocarcinoma［J］.Cancer Immunology Research,2015,3(10):1123-1129.
［23］YOYEN ERMIS D,TUNALI G,TAVUKCUOGLU E,et al.Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS［J］.Scientific Reports,2019,9(1):1-11.
［24］CHEN YQ,LI PC,PAN N,et al.Tumor-released autophagosomes induces CD4+T cell-mediated immunosuppression via a TLR2-IL-6 cascade［J］.Journal for Immunotherapy of Cancer,2019,7(1):1-16.
［25］GREEN MR,MONTI S,RODIG SJ,et al.Integrative analysis reveals selective 9p24.1 amplification,increased PD-1 ligand expression,and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma［J］.Blood,2010,116(17):3268-3277.
［26］KAPLAN MH,SCHINDLER U,SMILEY ST,et al.Stat6 is required for mediating responses to IL-4 and for the development of Th2 cells［J］.Immunity,1996,4(3):313-319.
［27］MA C,HORLAD H,PAN C,et al.Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines［J］.Journal of Clinical and Experimental Hematopathology,2017,57(1):21-25.
［28］LIANG SC,LATCHMAN YE,BUHLNABB JE,et al.Regulation of PD-1,PD-L1,and PD-L2 expression during normal and autoimmune responses［J］.European Journal of Immunology,2003,33(10):2706-2716.
［29］RAFTERY MJ,ABDELAZIZ MO,HOFMANN J,et al.Hantavirus-driven PD-L1/PD-L2 upregulation:an imperfect viral immune evasion mechanism［J］.Frontiers in Immunology,2018,9:2560.
［30］CAO S,WYLIE KM,WYCZALKOWSKI MA,et al.Dynamic host immune response in virus-associated cancers［J］.Communications Biology,2019,2(1):1-11.
［31］KATAOKA K,MIYOSHI H,SAKATA S,et al.Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas［J］.Leukemia,2019,33(7):1687-1699.
［32］SUN C,MEZZADRA R,SCHUMACHER TN.Regulation and function of the PD-L1 checkpoint［J］.Immunity,2018,48(3):434-452.
［33］程娜,田领章,刘炜.不同免疫检查点基因在急性髓细胞白血病中的表达与临床意义［J］.中国医师杂志,2019,21(8):1185-1189.
CHENG N,TIAN LZ,LIU W.The expression and clinical significance of immune checkpoints in acute myeloid leukemia［J］.Journal of Chinese Physician,2019,21(8):1185-1189.
［34］沙梦琪.儿童急性白血病中PD-1、PD-L1及PD-L2的表达及临床意义［D］.遵义:遵义医科大学,2021.
SHA MQ.The expression of PD-1,PD-L1 and PD-L2 in childhood acute leukemia and its clinical significance［D］.Zunyi:Zunyi Medical University,2021.
［35］WU Y,WEI J,CHEN X,et al.Comprehensive transcriptome profiling in elderly cancer patients reveals aging-altered immune cells and immune checkpoints［J］.International Journal of Cancer,2019,144(7):1657-1663.
［36］CHEN C,LIANG C,WANG S,et al.Expression patterns of immune checkpoints in acute myeloid leukemia［J］.Journal of Hematology & Oncology,2020,13(1):1-5.
［37］LIANG CF,ZHAO YJ,CHEN CT,et al.Higher TOX genes expression is associated with poor overall survival for patients with acute myeloid leukemia［J］.Front Oncol,2021,11:740642.
［38］YANG H,BUESO-RAMOS C,DINARDO C,et al.Expression of PD-L1,PD-L2,PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents［J］.Leukemia,2014,28(6):1280-1288.
［39］SAXENA K,HERBRICH SM,PEMMARAJU N,et al.A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia［J］.Cancer,2021,127(20):3761-3771.
［40］MCCLANAHAN F,RICHES JC,MILLER S,et al.Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eμ-TCL1 CLL mouse model［J］.Blood,2015,126(2):212-221.
［41］KORKMAZ S,ERDEM S,AKAY E,et al.Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies［J］.Turkish Journal of Medical Sciences,2019,49(1):265-271.
［42］马银娟,杨夏影,王莹,等.PD-1/PD-L1/2通路在多发性骨髓瘤中的研究进展［J］.肿瘤防治研究,2021,48(6):647-651.
MA YJ,YANG XY,WANG Y,et al.Research progress of PD-1/PD-L1/2 pathway in multiple myeloma［J］.Cancer Research on Prevention and Treatment,2021,48(6):647-651.
［43］马银娟,杨柯,杨夏影,等.初诊多发性骨髓瘤患者T细胞亚群和骨髓瘤细胞中PD-1、PD-L1及PD-L2的表达与意义［J］.肿瘤防治研究,2022,49(1):40-45.
MA YJ,YANG K,YANG XY,et al.Expression and significance of PD-1,PD-L1 and PD-L2 in T cell subsets and myeloma cells in newly diagnosed multiple myeloma patients［J］.Cancer Research on Prevention and Treatment,2022,49(1):40-45.
［44］GUO Y,FENG X,JIANG Y,et al.PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells［J］.Oncotarget,2016,7(30):48360.
［45］HORLAD H,MA C,YANO H,et al.An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands(PD-L1/2) on infiltrating macrophages in lymphoma［J］.Cancer Science,2016,107(11):1696-1704.
［46］LAGERLOF I,FOHLIN H,ENBLAD G,et al.Limited,but not eliminated,excess long-term morbidity in stage Ⅰ-ⅡA Hodgkin lymphoma treated With doxorubicin,bleomycin,winblastine,and dacarbazine and limited-field radiotherapy［J］.Journal of Clinical Oncology,2022,40(13):1487-1496.
［47］ROEMER MGM,ADVANI RH,LIGON AH,et al.PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome［J］.Journal of Clinical Oncology,2016,34(23):2690.
［48］CHEN X,KONG H,LUO L,et al.High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in relapsed/refractory classical Hodgkin lymphoma［J］.BMC Cancer,2022,22(1):1-8.
［49］GU Q,LI J,CHEN Z,et al.Expression and prognostic significance of PD-L2 in diffuse large B-cell lymphoma［J］.Frontiers in Oncology,2021,11:664032-664032.
［50］禹环,符丽梅.弥漫大 B 细胞淋巴瘤患者 PD-L1/PD-L2 表达水平与临床病理及预后的关系［J］.分子诊断与治疗杂志,2020,12(9):1163-1166.
YU H,FU LM.Relationship between PD-L1/PD-L2 and clinical pathology,prognosis in patients with diffuse large B cell lymphoma［J］.Journal of Molecular Diagnostics and Therapy,2020,12(9):1163-1166.
［51］KRITTIKARUX S,WUDHIKARN K,TANGNUNTACHAI N,et al.The influence of programmed cell death ligand 2(PD-L2) expression on survival outcome and tumor microenvironment in diffuse large B cell lymphoma［J］.Leukemia & Lymphoma,2020,61(14):3395-3403.
［52］KAROLOVA J,RADEK M,HELMAN K,et al.PD-1,PD-L1 and PD-L2 expression in mantle cell lymphoma and healthy population［J］.Folia Biologica,2020,66(4):117-122.
［53］马银娟,潘耀柱.PD-1/PD-L1通路在血液系统疾病中的研究进展［J］.现代肿瘤医学,2020,28(16):2905-2909.
MA YJ,PAN YW.Research update on PD-1/PD-L1 pathway in hematological diseases［J］.Modern Oncology,2020,28(16):2905-2909.
［54］师英庆,刘卓刚,王洪涛.PD-1/PD-L1在急性髓系白血病中的研究进展和临床应用［J］.现代肿瘤医学,2020,28(18):3241-3244.
SHI YQ,LIU ZG,WANG HT.Research progress and clinical application of PD-1/PD-L1 in acute myeloid leukemia［J］.Modern Oncology,2020,28(18):3241-3244.
［55］UMEZU D,OKADA N,SAKODA Y,et al.Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment［J］.Cancer Immunology,Immunotherapy,2019,68(2):201-211.
［56］VAN KEULEN VP,CIRIC B,RADHAKRISHNAN S,et al.Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12［J］.Clinical & Experimental Immunology,2006,143(2):314-321.
［57］VASATURO A,DI BLASIO S,PEETERS DGA,et al.Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination:a game of stop and go［J］.Frontiers in Immunology,2013,4:417.
［58］SASIKUMAR PG,SUDARSHAN NS,ADURTHI S,et al.PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy［J］.Communications Biology,2021,4(1):1-12.
［59］王亚丽,张丽军,成志勇,等.PD-1/PD-L1 通路在髓系肿瘤中的研究进展［J］.现代肿瘤医学,2021,29(10):1793-1797.
WANG YL,ZHANG LP,CHENG ZY,et al.Research progress of PD-1 and PD-L1 pathway in myeloid haematopoietic malignancy［J］.Modern Oncology,2021,29(10):1793-1797.